Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications

Oxid Med Cell Longev. 2017:2017:8023935. doi: 10.1155/2017/8023935. Epub 2017 Sep 25.


Long-term fluoroquinolone-associated disability (FQAD) after fluoroquinolone (FQ) antibiotic therapy appears in recent years as a significant medical and social problem, because patients suffer for many years after prescribed antimicrobial FQ treatment from tiredness, concentration problems, neuropathies, tendinopathies, and other symptoms. The knowledge about the molecular activity of FQs in the cells remains unclear in many details. The effective treatment of this chronic state remains difficult and not effective. The current paper reviews the pathobiochemical properties of FQs, hints the directions for further research, and reviews the research concerning the proposed treatment of patients. Based on the analysis of literature, the main directions of possible effective treatment of FQAD are proposed: (a) reduction of the oxidative stress, (b) restoring reduced mitochondrion potential ΔΨm,

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents* / adverse effects
  • Anti-Bacterial Agents* / therapeutic use
  • Fluoroquinolones* / adverse effects
  • Fluoroquinolones* / therapeutic use
  • Humans
  • Membrane Potential, Mitochondrial / drug effects*
  • Mitochondrial Diseases* / chemically induced
  • Mitochondrial Diseases* / metabolism
  • Mitochondrial Diseases* / pathology
  • Mitochondrial Diseases* / therapy
  • Oxidative Stress / drug effects*


  • Anti-Bacterial Agents
  • Fluoroquinolones